ABBV

by
Contributor since / Followers

5 months ago

vzphotos/iStock Editorial via Getty Images Back from recent lows, AbbVie (NYSE:ABBV) shares reached an all-time

by
Contributor since / Followers

5 months ago

by
Contributor since / Followers

5 months ago

by
Contributor since / Followers

5 months ago

vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) declares $1.64/share quarterly dividend, 5.8% increase from prior

by
Contributor since / Followers

5 months ago

AbbVie press release (NYSE:ABBV): Q3 Non-GAAP EPS of $3.00 beats by $0.08. Revenue of $14.46B

by
Contributor since / Followers

5 months ago

vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) is scheduled to announce Q3 earnings results on

by
Contributor since / Followers

5 months ago

vzphotos/iStock Editorial via Getty Images AbbVie (NYSE:ABBV) has agreed to acquire all outstanding equity of

by ONeil Trader
Contributor since 2012 / 8673 Followers

6 months ago

Summary: AbbVie will report Q3 2024 results next week and I expect to see a

by Brett Ashcroft Green
Contributor since 2022 / 5725 Followers

6 months ago

Summary: Healthcare stocks are both defensive and present a mean reversion opportunity, making them attractive

by
Contributor since / Followers

6 months ago

Michael Vi/iStock Editorial via Getty Images The U.S. Food and Drug Administration (FDA) has approved